Persistent Cigarette Smoking Attenuates Plaque Stabilization in Response to Lipid-Lowering Therapy: A Serial Optical Coherence Tomography Study

Xiling Zhang¹²†, Xiang Peng¹²†, Lulu Li¹², Huai Yu¹² and Bo Yu¹²*  
¹ Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China, ² The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, Harbin, China

Objective: This study aimed to investigate the effect of smoking on morphological changes in non-culprit plaques in acute coronary syndrome (ACS) patients at 1 year after percutaneous coronary intervention (PCI), using optical coherence tomography (OCT).

Background: Cigarette smoking is an important risk factor for coronary artery disease. However, the reasons for the high risk of re-infarction and worsened health among patients who continue to smoke after PCI remain unclear.

Methods: A total of 129 non-culprit plaques were identified from 97 ACS patients who underwent OCT imaging at the time of PCI and at 1-year follow-up. Patients were divided into the following three groups according to their smoking status at 1-year follow-up: persistent smoking group (n = 26), smoking cessation group (n = 29), and nonsmoking group (n = 42). Medical history, serum cholesterol level, coronary angiography data, and OCT-determined plaque morphology were analyzed among the three groups.

Results: Relative to baseline levels, the total cholesterol and low-density lipoprotein cholesterol levels significantly decreased in all three groups at 1-year follow-up after statin therapy (p < 0.05). The persistent smoking group had a relatively smaller fibrous cap thickness (FCT) and a higher incidence of thin-cap fibroatheroma (TCFA) than the other two groups at 1-year follow-up (p < 0.05), although the FCT increased and the incidence of TCFA decreased in all three groups.

Conclusions: Persistent smoking is associated with an attenuated effect of statin therapy on plaque stabilization in ACS patients.

Keywords: acute coronary syndrome, statin, smoking, fibrous cap thickness, thin-cap fibroatheroma

INTRODUCTION

Cigarette smoking is one of the most important risk factors for coronary artery disease and can induce coronary artery spasm, coronary artery plaque formation, plaque rupture or erosion, and coronary thrombosis through various mechanisms that lead to acute coronary syndrome (ACS) (1). A report on global and regional cardiovascular mortality indicated that more than 10% of
cardiovascular deaths were believed to be due to cigarette smoking (2). An American cohort study reported a higher mortality rate in current smokers with atherosclerosis and ischemic heart disease than in nonsmokers (3). Furthermore, patients who continue to smoke after percutaneous coronary intervention (PCI) have worse outcomes than those who successfully quit (4, 5). Although statins could reduce cardiovascular morbidity and mortality in current smokers, these remain high with respect to absolute incidence compared with those in smoking quitters and never smokers (6).

Owing to its extremely high resolution, optical coherence tomography (OCT) has been widely applied to explore the pathogenesis of ACS. With a resolution 10 times higher than that of intravascular ultrasound, OCT is considered superior for detecting fibrous cap thickness (FCT) and thin-cap fibroatheroma (TCFA) (7). The reasons that patients who continue to smoke after PCI have higher risks of re-infarction and worsened health remain unclear. This study aimed to investigate the effect of smoking on morphological changes in non-culprit plaques in ACS patients at 1 year after PCI using OCT.

**MATERIALS AND METHODS**

**Study Population**

We screened 247 patients who underwent OCT from 2009 to 2013 at the Second Affiliated Hospital of Harbin Medical University. Patients who (i) were diagnosed with ACS including ST-elevation myocardial infarction (STEMI), non-STEMI, and unstable angina, (ii) had OCT images of three vessels at the time of PCI and 1-year follow-up, and (iii) had at least one non-culprit/non-target lesion with diameter stenosis > 20%, as measured by quantitative coronary angiography (QCA), were included in the study. Patients who (i) had incomplete clinical histories or laboratory data, (ii) had OCT images of poor quality, (iii) underwent coronary artery bypass grafting, (iv) had chronic total occlusion or lesion at the site of previous stenting, and (v) stopped smoking prior to PCI were excluded. Among 247 patients, 97 with 129 non-culprit plaques were included in the analysis.

Patients were divided into the following three groups according to smoking status at the 1-year follow-up: persistent smoking (PS) group (n = 26 patients with 32 plaques), smoking cessation (SC) group (n = 29 patients with 40 plaques), and nonsmoking (NS) group (n = 42 patients with 57 plaques). The definitions of a smoker and a nonsmoker were based on the World Health Organization standard (8). A smoker was defined as an individual who smoked any tobacco product either daily or occasionally at the time of the survey, whereas a nonsmoker referred to an individual who did not smoke at all at the time of the survey. In our study, patients in the PS group were considered smokers who continued to smoke after PCI, whereas patients in the SC group were regarded as smokers who successfully quit smoking after PCI.

**Coronary Angiography Image Acquisition and Analysis**

Patients were pretreated with sufficient dual antiplatelet therapy (aspirin and clopidogrel) prior to coronary angiography. Coronary angiography data were analyzed by two investigators blinded to clinical information using the QCA analysis software package (Quantcor QCA version 5.0; Pie Medical Imaging BV, Maastricht, Netherlands). All non-culprit lesions with 20–70% diameter stenosis were included in our analyses. Reference diameter, minimum lumen diameter, diameter stenosis, and lesion length of non-culprit lesions were measured for the analysis.

**OCT Image Acquisition and Analysis**

OCT images were obtained using either a time-domain (M2/M3 Cardiology Imaging System; LightLab Imaging, Westford, MA, USA) or frequency-domain OCT system (C7-XR OCT Intravascular Imaging System; St. Jude Medical, St. Paul, MN, USA). Two independent reviewers blinded to clinical information analyzed the OCT images. In the event of disagreement between the two reviewers, a third professional investigator intervened to reach a consensus.

Anatomic landmarks such as side branches, calcifications, and stent edges were used to identify corresponding lesions on OCT images between baseline and follow-up.

The OCT images were assessed in accordance with the criteria of the Clinical Expert Consensus Document on OCT (9, 10). Lipid was identified as a diffusely bordered signal-poor region with attenuation by the overlying signal-rich layer. Lipid-rich plaque was semiquantified and was defined as a plaque with a lipid arc > 90° and FCT < 120 µm. The FCT of each lipid-rich plaque was calculated as the mean thickness of the thinnest three points, as visually estimated. TCFA was defined as a lipid-rich plaque with a maximum lipid arc > 90° and an FCT ≤ 65 mm. A lipid arc was measured at each 1-mm interval throughout the lipid-rich plaque. Moreover, the mean and maximum lipid arcs were recorded. The lipid index was computed by multiplying the mean lipid core arc by the lipid core length. Lipid core length, defined as the length of plaque with > 90° lipid arc, was measured in the longitudinal view. At follow-up, the OCT indexes described above were measured at the same sites via the same methodology according to the landmarks established at baseline.

**Statistical Methods**

All statistical analyses were performed using SPSS version 19.0 (IBM Corp., Armonk, NY, USA), and p-value < 0.05 was considered statistically significant. For the description of subjects’ demographic and clinical characteristics, categorical variables were presented as counts (percentages) and analyzed using chi-squared test or Fisher’s exact test. Continuous variables were expressed as mean ± standard deviation. Differences among the three groups were analyzed using analysis of variance or Kruskal–Wallis H test. Multiple comparisons were followed by post hoc tests and Bonferroni correction if the differences among the three groups were statistically significant, and p < 0.017.
was considered statistically significant. Owing to the presence of multiple plaques within a single subject, a generalized estimating equation approach was employed to identify independent predictors for the presence of TCFA and FCT. Variables included in the model were age, gender, hypertension, hyperlipidemia, diabetes mellitus (DM), statin use, and low-density lipoprotein cholesterol (LDL-C) level.

RESULTS
Study Population
A flow chart categorizing ACS patients based on their smoking status is presented in Figure 1. The baseline characteristics of study patients are summarized in Table 1. Significant differences in age (52.9 ± 6.5 years vs. 53.0 ± 11.9 years vs. 58.2 ± 7.5 years, p = 0.011) and gender (81 vs. 79 vs. 38%, p < 0.001) were observed among the three groups. Although the difference in age was not significant after multiple comparisons, smokers (including patients in both PS and SC groups) seemed to be younger than nonsmokers. Smokers comprised a higher proportion of males than nonsmokers (p = 0.001). Smokers with DM were fewer than nonsmokers (19 vs. 45% vs. 62%, p = 0.002). There was no difference in body mass index or hypertension among the three groups. More than 90% of patients were administered with aspirin, clopidogrel, and statin after PCI; nonetheless, the proportion of patients treated with statin did not significantly differ among the three groups. There was no change in antiplatelet and statin therapy at the 1-year follow-up among the three groups.

Laboratory Findings
The laboratory findings are presented in Table 2 and Figure 2. The total cholesterol (TC) and LDL-C levels were significantly different among the three groups at baseline (TC: 4.32 ± 0.9 mmol/L vs. 5.31 ± 1.05 mmol/L vs. 5.31 ± 1.26 mmol/L, p < 0.001; LDL-C: 2.13 ± 0.51 mmol/L vs. 3.04 ± 0.81 mmol/L vs. 2.78 ± 0.71 mmol/L, p < 0.001). The TC and LDL-C levels were lower in the PS group than in the SC and NS groups (p < 0.017). However, differences in the TC and LDL-C levels at the 1-year follow-up were not significant. Relative to the baseline, the TC and LDL-C levels significantly decreased in all three groups at the 1-year follow-up (p < 0.05). The change in TC level was smaller in the PS group than in the SC group (0.63 ± 1.05 mmol/L vs. 1.75 ± 1.11 mmol/L, p = 0.001). The triglyceride (TG) level did not significantly change in the PS group but significantly decreased in the SC and NS groups at the 1-year follow-up (SC: 2.40 ± 1.66 mmol/L vs. 1.51 ± 0.87 mmol/L, p < 0.001; NS: 2.56 ± 1.80 mmol/L vs. 1.68 ± 0.88 mmol/L, p < 0.001).

Angiographic Findings
Lesion location and angiographic findings are listed in Table 3. Diameter stenosis was similar among the three groups at baseline but seemed to have increased in the PS group compared with that in the other groups (p = 0.05). No significant difference in lesion location was observed among the three groups. Furthermore, no significant differences in minimum lumen diameter, reference diameter, and lesion length were noted among the three groups at either baseline or 1-year follow-up.

OCT Findings
The plaque characteristics identified by OCT are presented in Table 4 and Figure 3. Differences in FCT and TCFA between baseline and 1-year follow-up for each of the three groups are shown in Figure 4. The plaque amount per patient was similar among the three groups. Furthermore, no significant
<p>TABLE 1 | Baseline characteristics.</p>

| Variable         | PS group (n = 26) | SC group (n = 29) | NS group (n = 42) | p-value | p-value  
|------------------|------------------|------------------|------------------|--------|--------
|                  |                  |                  |                  |        |        
|                  | Age, years       | 52.9 ± 6.5       | 53.0 ± 11.9      | 58.2 ± 7.5 | 0.011 | 1.000  | 0.038 | 0.032 |
|                  |                  |                  |                  |        |        
|                  | Men, n (%)       | 21 (80.7%)       | 23 (79.3%)       | 16 (38.1%) | <0.001 | 0.893  | 0.001 | 0.001 |
|                  |                  |                  |                  |        |        
|                  | BMI, kg/m²       | 24.8 ± 2.9       | 25.2 ± 3.1       | 25.0 ± 2.6 | 0.838 |        |        |        |
|                  |                  |                  |                  |        |        
|                  | STEMI, n (%)     | 2 (7.7%)         | 9 (31.0%)        | 4 (9.6%)  | 0.033 | 0.031  | 0.796 | 0.021 |
|                  |                  |                  |                  |        |        
|                  | Hypertension, n (%) | 14 (53.8%) | 18 (62.0%) | 27 (64.3%) | 0.683 |        |        |        |
|                  |                  |                  |                  |        |        
|                  | DM, n (%)        | 5 (19.2%)        | 13 (44.8%)       | 26 (61.9%) | 0.002 | 0.043  | 0.001 | 0.155 |
|                  |                  |                  |                  |        |        
|                  | Statin, n (%)    | 24 (92.3%)       | 29 (100.0%)      | 40 (95.2%) | 0.287 |        |        |        |
|                  |                  |                  |                  |        |        
|                  | Rosuvastatin 10 mg | 5 (19.2%) | 3 (10.3%) | 13 (30.9%) | 0.110 |        |        |        |
|                  |                  |                  |                  |        |        
|                  | Atorvastatin 20 mg | 9 (34.6%) | 14 (48.3%) | 16 (38.1%) | 0.548 |        |        |        |
|                  |                  |                  |                  |        |        
|                  | Atorvastatin 60 mg | 5 (19.2%) | 12 (41.4%) | 9 (21.4%)  | 0.104 |        |        |        |
|                  |                  |                  |                  |        |        
|                  | Simvastatin 20 mg | 5 (19.2%) | 0 (0.0%)  | 1 (2.4%)   | 0.005 |        |        |        |
|                  |                  |                  |                  |        |        
|                  | Aspirin, n (%)   | 26 (100.0%)      | 29 (100.0%)      | 42 (100.0%) | 1.000 |        |        |        |
|                  |                  |                  |                  |        |        
|                  | Clopidogrel, n (%) | 25 (96.15%) | 29 (100.0%) | 42 (100.0%) | 0.268 |        |        |        |
|                  |                  |                  |                  |        |        
|                  | ACEI/ARB, n (%)  | 12 (46.2%)       | 16 (55.2%)       | 18 (42.8%) | 0.587 |        |        |        |
|                  |                  |                  |                  |        |        
|                  | Beta-blocker, n (%) | 16 (61.5%) | 16 (55.2%) | 28 (66.7%) | 0.618 |        |        |        |

Data are presented as n (%) or mean ± SD. PS, persistent smoking; SC, smoking cessation; NS, non-smoking; BMI, body mass index; STEMI, ST-elevation myocardial infarction; DM, diabetes mellitus; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

<ref>TABLE 2 | Laboratory findings for the three groups at baseline and 1-year follow-up.</ref>

| Variable       | Time          | PS group (n = 26) | SC group (n = 29) | NS group (n = 42) | p-value | p-value |
|----------------|---------------|------------------|------------------|------------------|--------|--------|
|                |               |                  |                  |                  |        |        |
| TC, mmol/L     | Baseline      | 4.32 ± 0.9       | 5.31 ± 1.05      | 5.31 ± 1.26      | <0.001 | 0.004  | 0.002 | 1.000 |
|                | Follow-up     | 3.7 ± 0.79       | 3.58 ± 0.67      | 4.05 ± 1.17      | 0.814  |        |        |        |
|                | Change over time | 0.63 ± 1.06     | 1.75 ± 1.11      | 1.27 ± 1.12      | 0.001  | 0.001  | 0.063 | 0.211 |
| LDL-C, mmol/L  | Baseline      | 2.13 ± 0.51      | 3.04 ± 0.81      | 2.78 ± 0.71      | <0.001 | <0.001 | 0.001 | 0.359 |
|                | Follow-up     | 1.72 ± 0.55      | 1.79 ± 0.55      | 2.01 ± 0.77      | 0.159  | 0.020  | 0.488 | 0.302 |
|                | Change over time | 0.41 ± 0.73     | 1.25 ± 0.91      | 0.77 ± 0.87      | 0.002  |        |        |        |
| TG, mmol/L     | Baseline      | 2.08 ± 1.31      | 2.40 ± 1.66      | 2.56 ± 1.80      | 0.508  |        |        |        |
|                | Follow-up     | 1.90 ± 1.23      | 1.51 ± 0.87      | 1.68 ± 0.88      | 0.333  |        |        |        |
|                | Change over time | 0.19 ± 0.98     | 0.90 ± 1.23      | 0.88 ± 1.53      | 0.073  |        |        |        |
| HDL-C, mmol/L  | Baseline      | 1.19 ± 0.32      | 1.25 ± 0.30      | 1.36 ± 0.33      | 0.082  |        |        |        |
|                | Follow-up     | 1.25 ± 0.39      | 1.2 ± 0.3        | 1.27 ± 0.57      | 0.810  |        |        |        |
|                | Change over time | −0.05 ± 0.35    | 0.05 ± 0.34      | 0.09 ± 0.51      | 0.374  |        |        |        |

Data are presented as mean ± SD. PS, persistent smoking; SC, smoking cessation; NS, non-smoking; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol.

Differences in FCT, lipid index, maximum lipid arc, lipid core length, and TCFA were observed among the three groups at baseline. FCT significantly increased in all three groups at the 1-year follow-up (PS: 62.44 ± 30.40 µm vs. 101.47 ± 65.13 µm, p = 0.001; SC: 65.60 ± 18.96 µm vs. 152.18 ± 68.69 µm, p < 0.001; NS: 65.14 ± 25.15 µm vs. 140.37 ± 83.46 µm, p < 0.001), although the change in FCT was relatively smaller in the PS group than in the other groups at the 1-year follow-up (p = 0.016). The incidence of TCFA decreased in the SC and NS groups at the 1-year follow-up (SC: 62.50 vs. 12.5%, p < 0.001; NS: 63.16% vs. 12.28%, p < 0.001); however, the incidence of TCFA remained higher in the PS group at the 1-year follow-up (p = 0.006). The lipid index and lipid core length were higher in the PS group than in the SC group at the 1-year follow-up (p = 0.011). Compared with the lipid index at baseline, lipid index at the 1-year follow-up decreased in all three groups (p < 0.05). There was no significant difference in the changes in mean lipid arc and maximum lipid arc among the three groups.

Generalized Estimating Equation Results

After adjustment for age, gender, hypertension, DM, statin use, and LDL-C level, TCFA was more frequently observed in the PS group than in the SC and NS groups (PS vs. SC,
FIGURE 2 | Changes in cholesterol level in each group observed after 1 year. TC and LDL-C levels decreased in all three groups after 1 year of statin therapy. TG level significantly decreased in the SC and NS groups, but not in the PS group. TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol.
TABLE 4 | OCT findings.

| OCT variable          | Time                  | PS group (n = 32)          | SC group (n = 40)          | NS group (n = 57)          | p-value     |
|-----------------------|-----------------------|---------------------------|---------------------------|---------------------------|-------------|
| Average plaque number | Baseline              | 1.23 ± 0.514              | 1.38 ± 0.862              | 1.36 ± 0.759              | 0.721       |
|                       | Follow-up             | 1.99 ± 0.795              | 2.35 ± 0.972              | 2.14 ± 0.795              | 0.066       |
| Lipid index           | Baseline              | 2648.83 ± 1962.41         | 2643.14 ± 1509.66         | 2643.14 ± 1509.66         | 0.988       |
|                       | Follow-up             | 2215.43 ± 1654.17         | 2215.43 ± 1654.17         | 2215.43 ± 1654.17         | 0.001       |
| FCT, µm               | Baseline              | 12 (37.5%)                | 14 (43.75%)               | 15 (37.5%)                | 0.674       |
|                       | Follow-up             | 16 (50%)                  | 16 (50%)                  | 16 (50%)                  | 0.878       |
| TCFA, n (%)           | Baseline              | 0 (0%)                    | 0 (0%)                    | 0 (0%)                    | 0.862       |
|                       | Follow-up             | 0 (0%)                    | 0 (0%)                    | 0 (0%)                    | 0.862       |

Data are presented as n (%) or mean ± SD. OCT, optical coherence tomography; PS, persistent smoking; SC, smoking cessation; NS, non-smoking.

DISCUSSION

The main findings of the present study were as follows: (i) statin therapy could increase FCT and decrease the incidence of TCFA and the lipid index of non-culprit plaques in ACS patients regardless of smoking; (ii) patients who continued to smoke after PCI had a relatively smaller FCT and a higher incidence of TCFA than patients who stopped smoking or never smoked at the 1-year follow-up; and (iii) the changes in FCT, TCFA, and lipid index were similar between the SC and NS groups. After adjustment for age, gender, hypertension, DM, statin use, and LDL level, smoking was independently correlated with a higher incidence of TCFA and a relatively smaller FCT after PCI.

Effect of Statin on LDL-C and Plaque

Pathological studies have confirmed that LDL-C, particularly oxidized LDL, could induce atherosclerosis by stimulating monocyte infiltration as well as smooth muscle cell migration and proliferation (11). A previous study reported the association between the severity of LDL-C level elevation and a higher risk of mortality among healthy subjects (12). The relative risk of major cardiovascular events decreases by 23% for every 1 mmol/L reduction in LDL-C level (13). Statin therapy can reduce cardiovascular morbidity and mortality regardless of gender and risk (14, 15) and all-cause mortality in patients with lower LDL-C level (16). Statins have been proven to reduce the frequency of TCFA and plaque volume by decreasing serum atherogenic lipoproteins and inflammatory biomarkers (17–19). In our study,
FIGURE 3 | Changes in plaque characteristics for each group at baseline and 1-year follow-up. In the persistent smoking group, the fibrous cap thickness (FCT) was 0.05 mm with a lipid arc of 117.9° at baseline (A) and 0.08 mm with a lipid arc of 161.5° at the 1-year follow-up (B). In the smoking cessation group, the FCT was 0.04 mm with a lipid arc of 138.3° at baseline (C) and 0.11 mm with a lipid arc of 95.7° at the 1-year follow-up (D). In the nonsmoking group, the FCT was 0.11 mm with a lipid arc of 235.7° at baseline (E) and 0.25 mm with a lipid arc of 157.3° at the 1-year follow-up (F).

the TC and LDL-C levels decreased in all three groups after 1 year of statin therapy. Moreover, the FCT increased, whereas the incidence of TCFA decreased, which were consistent with the results of previous studies mentioned above.

Cigarette Smoking Affects Lipid and Lipoprotein Levels
Campbell et al. (20) summarized the unfavorable effects of cigarette smoking on lipid and lipoprotein levels and reported
that cigarette smoking could increase the TC, TG, and LDL-C levels. Furthermore, cigarette smoking can alter the critical enzymes for lipid transport, lowering lecithin–cholesterol acyltransferase activity and altering both cholesteryl ester transfer protein and hepatic lipase activities (21). These factors can favor the progression of atherosclerosis. Although the TC, LDL-C, and TG levels declined in all three groups at the 1-year follow-up, the changes in TC, LDL-C, and TG levels were less considerable in the PS group than in the SC and NS groups. Nevertheless, the PS group had a relatively smaller FCT and a higher incidence of TCFA than the other groups. Based on the conclusion of previous studies, the findings of our study indicate that cigarette smoking attenuated the stabilizing effect of statin on the vulnerable plaque.

**Effect of Cigarette Smoking on Plaque Vulnerability**

Plaque vulnerability is a major risk factor for ACS and depends on the plaque's lipid composition, FCT, degradation of extracellular matrix proteins, inflammatory cell recruitment, and intraplaque hemorrhage (22). Cigarette smoking has been shown to be independently associated with lipid-rich plaques and contributes to an increased risk of plaque vulnerability (23, 24). As the major component of cigarette, nicotine has been indicated to potentiate the proatherogenic effects of oxidized low-density lipoprotein (oxLDL) by stimulating and upregulating macrophage CD36 signaling (25). Thus, cigarette smoking potentiates endothelial dysfunction by enhancing oxLDL (26). Cigarette smoking can downregulate n-prolyl-4-hydroxylase, which contributes to the development of a thin fibrous cap in atherosclerotic plaques among smokers (27). Biglycan has recently been indicated as a major source of low-density lipoprotein in the normal arterial intima–media layer. Biglycan mRNA can be enhanced by cigarette smoking and appears to be associated with a proatherogenic profile (28). Cigarette smoking induces inflammation and oxidative stress, potentially increasing matrix metalloproteinase expression within atherosclerotic plaques, particularly at the shoulder regions, in which increased stress and matrix degradation can result in fibrous cap rupture (29). In our study, the PS group had more TCFA, relatively smaller FCT, and higher lipid index at 1-year follow-up than the SC and NS groups. TCFA has been considered a strong predictor of ACS (30). The results of our study might explain why smoking patients are at a higher risk of major adverse cardiovascular events after PCI.

**Smoking Status Affects the Prognosis of Patients After PCI**

Approximately one-third of ACS patients who smoke cannot quit smoking even after PCI, which worsens their outcomes compared with those of patients who successfully quit. An analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial revealed that smoking might be an independent predictor of high 1-year mortality among patients presenting with non-ST-elevation ACS (31). Other studies reported that patients who continued to smoke after PCI were at higher risk of Q-wave infarction and death than nonsmokers and that smoking cessation either before or after PCI was beneficial (4, 32). Smoking cessation could persistently improve endothelial function, which may exert a mediating effect and reduce the risk of cardiovascular diseases (33). Cigarette smoking has a broad impact on genome-wide methylation, by which cigarette smoking predisposes smokers to heart disease. Nonetheless, former smokers have fewer methylated genes than current smokers, indicating persistent altered methylation with attenuation after cessation (34). In our study, the TC, LDL-C, and TG levels notably declined in the SC group, and the SC group had a larger FCT and a lower incidence of TCFA than persistent smokers. These results were similar to those of the NS group, suggesting that SC combined with statin therapy could stabilize the vulnerable plaque.
Study Limitations
This study has several limitations. First, it is a retrospective, single-center study with a small sample; therefore, it is limited by the possibility of selection bias. Our study necessitated subjects to have both baseline and 1-year OCT images, and the OCT images were also required to include non-culprit coronary arteries; all of these limited the sample size. Second, passive smoking history, as well as the quantification and duration of smoking history, was not considered in this study. Third, the ostial and distal segments of the coronary arteries were not considered in our study because of OCT imaging limitations, which might lead to bias. Finally, owing to the limitations of the current OCT imaging system, some fibrous plaques might have been misdiagnosed as TCFA.

CONCLUSIONS
In the present study, although statin therapy decreased the TC and LDL-L levels and stabilized the plaque, patients who continued smoking after PCI had a relatively smaller FCT and a higher incidence of TCFA than patients in the SC and NS groups. These results indicate that cigarette smoking might attenuate the stabilizing effect of statin on the vulnerable plaque and might explain why smokers have worse endpoints than nonsmokers and smoking quitters. The results highlight the importance of providing early SC aids to patients who smoke.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

REFERENCES
1. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. (2004) 43:1731–7. doi: 10.1016/j.jacc.2003.12.047
2. Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. Circulation. (2005) 112:489–97. doi: 10.1161/CIRCULATIONAHA.104.21708
3. Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, et al. Smoking and mortality—beyond established causes. N Engl J Med. (2015) 372:631–40. doi: 10.1056/NEJMSa1407211
4. Jang J, Buchanan DM, Gosch KL, Jones PG, Sharma PK, Shafiq A, et al. Association of smoking status with health-related outcomes after percutaneous coronary intervention. Circ Cardiovasc Interv. (2015) 8:e002226. doi: 10.1161/CIRCINTERVENTIONS.114.002226
5. Liu J, Zhu ZY, Gao CY, Wang XP, Zhang Y, Jin WD, et al. Long-term effect of persistent smoking on the prognosis of Chinese male patients after percutaneous coronary intervention with drug-eluting stent implantation. J Cardiovasc. (2013) 62:283–8. doi: 10.1016/j.jcc.2013.05.010
6. Athyros VG, Tziomalos K, Katsiki N, Gossios TD, Giouleme O, Anagnostis P, et al. The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. Curr Vasc Pharmacol. (2013) 11:779–84. doi: 10.2174/15701611131100400016
7. Fujiw K, Hao H, Shibuya M, Imanaka T, Fukunaga M, Miki K, et al. Accuracy of OCT, grayscale IVUS, and their combination for the diagnosis of coronary TCFA: an ex vivo validation study. JACC Cardiovasc Imaging. (2015) 8:451–60. doi: 10.1016/j.jcmg.2014.10.015

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the ethics committee of the Second Affiliated Hospital of Harbin Medical University (Harbin, China). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS
XZ and XP made substantial contributions to conception, design, and planning of the study. LL and HY participated in interpretation of data and statistical analyses. BY were responsible for the overall content and served as guarantor. All authors were involved in reporting the results of this study and read and approved the final version of the submitted manuscript.

FUNDING
BY received research grants from the National Natural Science Foundation of China (Grant no. 81330033) and the National Key R&D Program of China (Grant No. 2016YFC1301100).

ACKNOWLEDGMENTS
We would like to thank all of our coworkers who contributed to this study and assisted in revising the manuscript.

8. Guidelines for Controlling and Monitoring the Tobacco Epidemic. Geneva: World Health Organization (1998). p. 76–7.
9. Prati F, Regar E, Mintz GS, Arbustini E, Di Mario C, Jang IK, et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J. (2010) 31:401–15. doi: 10.1093/eurheartj/ehp433
10. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the international working group for intravascular optical coherence tomography standardization and validation. J Am Coll Cardiol. (2012) 59:1058–72. doi: 10.1016/j.jacc.2011.09.079
11. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. (2010) 24:401–15. doi: 10.1093/eurheartj/ehp433
12. Seguro F, Bongard V, Bérard E, Taraszkiewicz D, Ruidavets JB, Ferrières J, et al. Dutch lipid clinic network low-density lipoprotein cholesterol criteria are associated with long-term mortality in the general population. Arch Cardiovasc Dis. (2015) 108:511–8. doi: 10.1016/j.acvd.2015.04.003
13. Silverman MG, Ference BA, Im K, Wiviott SD, Guagliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. (2016) 316:1289–97. doi: 10.1001/jama.2016.13985
14. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. (2015) 385:397–405. doi: 10.1016/S0140-6736(14)61368-4
15. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. (2012) 380:381–90. doi: 10.1016/S0140-6736(12)60367-5

16. Tsujimoto T, Kajio H, Sugiyama T. Statin therapy in patients with low serum levels of low-density lipoprotein cholesterol. Am J Cardiol. (2017) 120:1947–54. doi: 10.1016/j.amjcard.2017.08.011

17. Komukai K, Kubo T, Kitabata H, Matsuo Y, Ozaki Y, Takarada S, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. (2014) 64:2207–17. doi: 10.1016/j.jacc.2014.08.045

18. Park SJ, Kang SI, Ahn JM, Chang M, Yun SC, Roh JH, et al. Effect of statin treatment on modifying plaque composition: a double-blind, randomized study. J Am Coll Cardiol. (2016) 67:1772–83. doi: 10.1016/j.jacc.2016.02.014

19. Nilsson J. Atherosclerotic plaque vulnerability in the statin era. Eur Heart J. (2017) 38:1638–44. doi: 10.1093/eurheartj/ehx143

20. Dirican M, Sarandöl E, Ulukaya E, Tokullugil HA. Effects of smoking on serum lipid and lipoprotein concentrations and lecithin: cholesterol acyltransferase activity. J Med Invest. (1999) 46:169–72.

21. Chelland Campbell S, Moffatt RJ, Stamford BA. Smoking and smoking cessation – the relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis. (2008) 201:225–35. doi: 10.1016/j.atherosclerosis.2008.04.046

22. Ambrose JA, Srikanth S. Vulnerable plaques and patients: improving prediction of future coronary events. Am J Med. (2010) 123:10–6. doi: 10.1016/j.amjmed.2009.07.019

23. Abtahian F, Yonetsu T, Kato K, Jia H, Vergallo R, Tian J, et al. Comparison by optical coherence tomography of the frequency of lipid coronary plaques in current smokers, former smokers, and nonsmokers. Am J Cardiol. (2014) 114:674–80. doi: 10.1016/j.amjcard.2014.05.056

24. Kumagai S, Amano T, Takashima H, Waseda K, Kurita A, Ando H, et al. Impact of cigarette smoking on coronary plaque composition. Coron Artery Dis. (2015) 26:60–5. doi: 10.1097/MCA.0000000000000168

25. Zhou MS, Chadipiralla K, Mendez AJ, James EA, Silverstein RL, Webster K, et al. Nicotine potentiates proatherogenic effects of oxLDL by stimulating and upregulating macrophage CD36 signaling. Am J Physiol Heart Circ Physiol. (2013) 305:H563–74. doi: 10.1152/ajpheart.00042.2013

26. Heitzer T, Ylä-Herttuala S, Luoma J, Kurz S, Münzel T, Just H, et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation. (1996) 93:1346–53. doi: 10.1161/01.CIR.93.7.1346

27. Ravendran M, Senthil D, Utama B, Shen Y, Dudley D, Wang J, et al. Cigarette suppresses the expression of P4Halpha and vascular collagen production. Biochem Biophys Res Commun. (2004) 323:592–8. doi: 10.1016/j.bbrc.2004.08.129

28. Mandraffino G, Imbalzano E, Mamone F, Aragona CO, Lo Gullo A, D’Ascola A, et al. Biglycan expression in current cigarette smokers: a possible link between active smoking and atherogenesis. Atherosclerosis. (2014) 237:471–9. doi: 10.1016/j.atherosclerosis.2014.10.024

29. Perls-Tei T, Lee RT. Smoking, metalloproteinases, and vascular disease. Arterioscler Thromb Vasc Biol. (2006) 26:250–6. doi: 10.1161/01.ATV.0000199268.27395.4f

30. Iannaccone M, Quadri G, Taha S, D’Ascenzo F, Montefusco A, Omede P, et al. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. (2016) 17:1128–37. doi: 10.1093/ehjci/jev283

31. Robertson JO, Ebrahimi R, Lansky AJ, Mehran R, Stone GW, Lincoff AM. Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUTY Trial (Acute Catheterization and Urgent Intervention Triage Strategy). JACC Cardiovasc Interv. (2014) 7:372–9. doi: 10.1016/j.jcin.2013.11.017

32. Hasdai D, Garratt KN, Grill DE, Lerman A, Holmes DR Jr. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med. (1997) 336:555–61. doi: 10.1056/NEJM199703133361103

33. Johnson HM, Gossett LK, Piper ME, Aeschlimann SE, Korcarz CE, Baker TB, et al. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol. (2010) 55:1988–95. doi: 10.1016/j.jacc.2010.03.002

34. Joshanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR, et al. Epigenetic signatures of cigarette smoking. Circ Cardiovasc Genet. (2016) 9:436–47. doi: 10.1161/CIRCGENETICS.116.001506

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.